Medical Oncologist
HER2-positive breast cancer
Trastuzumab and Pertuzumab: — Why This Combination Is Used
Trastuzumab and pertuzumab are two antibodies that each block a different part of the same HER2 protein. When your oncologist adds chemotherapy and hormone therapy, each component is doing a different job — and understanding what that job is can help you know what to expect.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Two antibodies, one protein — Trastuzumab and pertuzumab each attach to a different section of the HER2 protein, blocking two separate growth routes at the same time.
- Chemotherapy adds direct cell killing — The antibodies block signals. Chemotherapy kills cells that are already dividing. Together they work at two levels.
- Hormone therapy closes a second door — If your tumour also has hormone receptors, hormone therapy is added to block that separate growth signal.
- Given as day care — The antibody infusions are given as day care at CION centres. You do not need to stay overnight.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Trastuzumab and pertuzumab are two antibodies that block the HER2 growth signal from different angles at the same time. Chemotherapy kills dividing cells while those signals are blocked. If your tumour also has hormone receptors, hormone therapy addresses that second growth signal. Each component targets a different weakness in the same cancer.
Why are two HER2 antibodies used at the same time?
HER2 is a protein on the surface of some cancer cells that acts as a permanently switched-on instruction to grow and divide.
Trastuzumab attaches to one section of the HER2 protein and disrupts one of the main signalling routes that protein uses.
Pertuzumab attaches to a different section and prevents HER2 from pairing with a partner protein called HER3. That pairing creates a second growth route that trastuzumab does not reach on its own.
Using both together means neither route is available. ESMO and NCCN guidelines describe this dual blockade as the standard approach for HER2-positive breast cancer.
What does chemotherapy add to the two antibodies?
The antibodies block the growth signal. They do not directly kill cancer cells that are already present.
Chemotherapy kills cells that are actively dividing.
Adding chemotherapy to the dual HER2 blockade targets the cancer at two levels at once: the signal driving growth, and the cells already growing.
Your oncologist will choose the chemotherapy agent based on your specific situation. Docetaxel is among the agents used in this setting, as reflected in ESMO and NCCN guidelines, though the exact choice depends on your case.
Why is hormone therapy included?
Some HER2-positive tumours also carry oestrogen or progesterone receptors. This is described as a HER2-positive, hormone receptor-positive tumour.
A tumour with both receptor types has two separate growth signals, not one.
The HER2 antibodies address the HER2 signal. Hormone therapy — usually an aromatase inhibitor or tamoxifen — addresses the hormone signal.
Whether hormone therapy is part of your regimen depends on your tumour's receptor test results, which your oncologist will have established from your biopsy report.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What happens during a treatment cycle?
Blood tests and heart scan
Before starting and regularly throughout treatment, you will have blood tests and a heart scan — usually an echocardiogram. Trastuzumab can affect heart function in a proportion of patients, so these checks are part of the standard protocol.
Day care infusion
Trastuzumab and pertuzumab are given as intravenous infusions in day care. You come in, receive the infusions, and go home the same day.
Chemotherapy in the same visit
Chemotherapy is usually given in the same day care appointment. Your team will tell you the order and the total time to allow for the visit.
Observation before you leave
After your infusions, you stay for a short observation period so the team can check for any immediate reactions before you go home.
Hormone therapy at home
If hormone therapy is part of your plan, you take it as a daily tablet at home. It continues between infusion cycles and often for years after the infusions finish.
Next cycle
Your regimen will run on a regular cycle. Your team will give you a treatment calendar so you know your infusion dates in advance.
What else should you know about this combination?
Will I lose my hair on this regimen?
Hair loss is caused by chemotherapy, not by the HER2 antibodies. Whether you lose your hair depends on which chemotherapy is chosen. Docetaxel, which is commonly used with this combination, typically causes significant hair loss. It usually begins a few weeks after the first cycle and grows back after chemotherapy ends. The antibodies themselves do not cause hair loss.
How long do I take trastuzumab and pertuzumab for?
In the early breast cancer setting, NCCN and ESMO guidelines recommend completing a defined full course of trastuzumab from when it starts. Pertuzumab is given for the same planned duration when it is part of the regimen. In the metastatic setting, both antibodies are usually continued for as long as the treatment is working and side effects are manageable. Your oncologist will tell you the planned duration for your specific situation at the outset.
Why does my heart need monitoring throughout treatment?
Trastuzumab can reduce the pumping function of the heart in a proportion of patients. This is usually reversible when it is identified early, which is why regular heart scans are part of the standard monitoring protocol. If a significant change is found, treatment may be paused while the heart recovers. Most people complete their full course without a cardiac problem, but the checks are not optional — they are what makes it safe to continue.
Can chemotherapy stop while the antibodies continue?
Yes. In many regimens, chemotherapy runs for a defined number of cycles and then stops, while the HER2 antibodies continue for the full planned duration. This is a deliberate part of the treatment plan, not an indication that something has gone wrong. If chemotherapy is stopped early for a different reason — such as side effects — your oncologist will explain what happens to the rest of the treatment.
Is there a version that does not need a drip?
A subcutaneous fixed-dose combination of pertuzumab and trastuzumab is available in some countries and at some centres. It is given as an injection under the skin rather than through a drip, and the administration time is shorter. Whether it is available at CION depends on current approvals and supply at your treatment centre. Ask your oncologist whether it is an option for you.
Will this combination work if I have had trastuzumab before?
Prior exposure to trastuzumab does not automatically rule out using it again. Your oncologist will consider what you received before, how your cancer responded, how long ago it was, and what the current treatment aim is. In some situations the same antibody is continued; in others, different HER2-targeted agents may be more appropriate. This is worth discussing directly with your oncologist, with your previous treatment records available.
Did you know?
HER2-positive breast cancer was historically one of the more aggressive subtypes of the disease.
The introduction of trastuzumab, and then the addition of pertuzumab for dual blockade, changed outcomes to the point that ASCO and ESMO now describe early-stage HER2-positive disease as one of the most treatable forms of breast cancer with modern regimens.
This shift is one of the most frequently cited examples of what targeted therapy can achieve when the right tumour target is identified.
Source: ASCO and ESMO Clinical Practice Guidelines for Breast Cancer
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long does each infusion appointment take?
The first cycle takes the longest because each infusion runs more slowly to watch for reactions — the full appointment can take most of a day. From the second cycle onwards, if the first was well tolerated, infusion times are typically shorter. Your team will give you an expected time for your regimen. Plan for the first visit to take longer than you expect and arrange transport accordingly.
Is this combination used for cancers other than breast cancer?
Trastuzumab is approved for HER2-positive gastric and gastro-oesophageal junction cancer as well as breast cancer. Pertuzumab is currently approved for HER2-positive breast cancer. The combination of both antibodies together is used in breast cancer. If you have a different HER2-positive cancer, your oncologist will explain which parts of the regimen apply to your diagnosis.
What is the difference between this regimen and standard chemotherapy?
Standard chemotherapy kills dividing cells broadly, without distinguishing between cancer cells and normal ones. The HER2 antibodies are targeted specifically to the HER2 protein, which is overexpressed on HER2-positive cancer cells. Hormone therapy, if included, targets a specific receptor on the tumour. The combination acts through several different mechanisms at once, with the antibody and hormone components being more targeted than chemotherapy alone.
Will this treatment affect my fertility?
Chemotherapy can affect fertility, and the extent depends on the specific agent used, the doses, and your age. The HER2 antibodies are not recommended during pregnancy because of risks to the developing baby, and effective contraception is advised throughout treatment and for a period afterwards. If fertility is important to you, raise this before treatment starts — options to preserve fertility need to be arranged before chemotherapy begins, not during it.
Can I take my usual medicines during treatment?
Tell your oncology team about every medicine you are taking — prescription, over-the-counter, and any herbal or Ayurvedic preparations. Some supplements and herbal remedies can interact with cancer treatment in ways that are not always obvious. This applies throughout the entire duration of treatment, not just at the start. Do not stop any prescribed medication without asking your treating team first.
What symptoms should I watch for at home between cycles?
Call your team the same day if you develop a fever, any sign of infection, chest pain, unusual breathlessness, or significant swelling in your legs. Breathlessness and leg swelling can be early signs of heart changes. Fever during chemotherapy can indicate low white cell counts that need prompt assessment. Your team will give you a list of symptoms specific to your regimen and a number to call out of hours — keep both accessible.